Inmune Bio Inc. announced the completion of the third and highest dose cohort of its Phase I trial for INKmune, a therapy for metastatic castration-resistant prostate cancer, enabling the start of the Phase II high dose cohort.
AI Assistant
INMUNE BIO INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.